Octapharma Study Demonstrates Cutaquig Efficacy & Safety

Octapharma  presented clinical research results at the Clinical Immunology Society Annual Meeting in Atlanta demonstrating the efficacy and safety of cutaquig [Immune Globulin Subcutaneous (Human) – hipp], a 16.5% immune globulin solution for subcutaneous infusion indicated for treatment of primary humoral immunodeficiency (PI) in adults.

“Subcutaneously administered immunoglobulin (SCIG) is increasingly used to treat patients with primary immunodeficiencies,” said Octapharma USA President Flemming Nielsen. “In addition to not requiring venous access, SCIG has few systemic side effects and can help improve patient quality of life. The evaluation of adverse events and infusion site reactions during the study showed that subcutaneous administration of cutaquig was well tolerated and safe in the assessed patient population.”

The clinical trial’s primary endpoint of preventing serious bacterial infections (SBIs) was met as none of the patients experienced an SBI during the study. Based on historical data, an SBI rate of less than 1 per person a year provides substantial evidence of efficacy.

The study, titled Efficacy, Safety and Tolerability of a Subcutaneous Human Immunoglobulin 16.5% (cutaquig) in Adult Patients with Primary Immune Deficiencies, further reported a rate of other infections per person a year of 2.73 with 65% of the infections being mild and 35% moderate in intensity. Eighty-five percent of infusions had no site reactions.

“The patients were extremely thankful to be able to use the subcutaneous method of administration with cutaquig as this provided a safe method to do the infusions at home avoiding the long and often tedious travel to the hospital for treatment,” said Dr. Elena Latysheva of the National Research Center Institute of Immunology FMBA in Moscow, Russia.

“This study corroborates the pivotal global cutaquig trial recently published in Frontiers in Immunology, where also none of the patients experienced a serious bacterial infection,” said Dr. Roger H. Kobayashi, UCLA School of Medicine Clinical Professor, Division of Pediatric Allergy and Immunology.

Cutaquig (Immune Globulin Subcutaneous (Human) – hipp) is a 16.5% immune globulin solution for subcutaneous infusion indicated for treatment of primary humoral immunodeficiency (PI) in adults.

Thrombosis may occur with immune globulin products, including cutaquig. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors.

For patients at risk of thrombosis, administer cutaquig at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity.

Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein products manufacturers in the world and has been committed to patient care and medical innovation since 1983. Its core business is the development and production of human proteins from human plasma and human cell lines. Octapharma employs approximately 8,314 people worldwide to support the treatment of patients in over 115 countries with products across the following therapeutic areas: Hematology (coagulation disorders), Immunotherapy (immune disorders) and Critical Care. The company’s American subsidiary, Octapharma USA, is located in Hoboken, N.J. Octapharma operates three state-of-the-art production sites licensed by the FDA, providing a high level of production flexibility. For more information, please visit www.octapharmausa.com.